Related Experiment Video
Updated: Sep 17, 2025

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
Published on: June 14, 2024
Disarming myeloid resistance in CAR T therapy
John M Warrington1, Nathan Singh1
1Division of Oncology, Section of Cellular Therapy, Washington University School of Medicine, St. Louis, MO, USA; Center for Gene and Cellular Immunotherapy, Washington University School of Medicine, St. Louis, MO, USA.
None:
Uncovering mechanisms of resistance to chimeric antigen receptor (CAR) T cell therapy for B cell lymphoma is of paramount importance. In this issue of Cancer Cell, Stahl et al. identify a CSF1R+ myelo-monocytic population that disrupts CAR T cell function and show that inhibition of CSF1R enhances efficacy of CD19-targeted CAR T cells.
More Related Videos
12:55Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
Related Concept Videos
Treatment Resistant Cancers
Tumor Immunotherapy